Skip to content

Medical Affairs

Intelligence Hub

Overview

Home
My Work
Command Center

Plan & execute

Medical Plans
Launch Readiness
Budget & Resources
Risks & Decisions

Field & science

Engagements
Insights
Evidence Generation

Communicate

Publications
Congresses
Medical Information

Govern

Reports
Data Quality
Administration

Helixor Therapeutics

Sample data · FY2026

Scope·4 products·FY2026

HODr. Helen OkaforGlobal Head of Medical Affairs

EngagementsENG-0165

Scientific exchange · Dr. Ingrid Bauer

21 Jul 2026 · Phone · Dr. Ingrid Bauer, Hospital Clínic Barcelona · MSL Luis Ortega · Lumeva

ReviewedVeeva CRMENG-0165—

Capture insight from this engagement

Location: Hospital Clínic Barcelona
Therapeutic area: Neurology
Country: Spain
Stakeholder tier: Tier 1
Strategic objective: Not linked
Initiative: Not linked
MSL: LOLuis OrtegaMSL, Neurology (Iberia)
Product: Lumeva (lumevarin)

Topics discussed

Chronic migraine data
Medication-overuse headache

Scientific content used

LMV persistence data summary

Questions raised

What is the persistence rate at 18 months in real-world cohorts?
Is there guidance on switching from a monoclonal antibody?

Notes

Scientific exchange with general neurologist at Hospital Clínic Barcelona. Discussed chronic migraine data, medication-overuse headache.

Insights captured (1)

Capture insight

INS-0069Low
Chronic migraine data
Chronic migraine data: request for data reported by general neurologist (ES).
Outcome recorded

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

No follow-ups recorded.

Quality ratings

1–5, rated at review

Scientific relevance: 5
Strategic relevance: 5
Depth of exchange: 1
Actionability: 3

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0165

Audit history (0)

All create, update and approval events for this record

No audit events in sample data